Application of 18F-FDG PET/CT Metabolic Parameters Combined with Serum FOXM1 in the Diagnosis of Lymph Node Metastasis in Colorectal Cancer

doi:10.7517/issn.1674-0475.220717

Abstract

Abstract: This study investigated the value of ¹⁸F-fluorodeoxyglucose (FDG) positron emission/computed tomography (PET/CT) metabolic parameters combined with serum forkhead box protein M1 (FOXM1) in the diagnosis of lymph node metastasis of colorectal cancer. A total of 103 patients with colorectal cancer were included in this study, and the lymph node metastasis was confirmed by pathological examination, and then the patients were divided into the metastasis group (51 cases) and the non-metastasis group (52 cases). All patients underwent ¹⁸F-FDG PET/CT examination, and then three metabolic parameters of maximum normalized uptake value (SUVmax), total glycolysis (TLG) and tumor metabolic volume (MTV) were obtained. In addition, serum FOXM1 levels of patients were detected by the ELISA method. The results showed that the SUVmax of non-metastasis was significantly higher than that of metastasis group (P<0.001). The MTV and TLG of the non-metastatic group was significantly lower than that of the metastatic group (P<0.001). Serum FOXM1 in the non-metastatic group was significantly lower than that in the metastatic group (P<0.001). Serum FOXM1 was significantly negatively correlated with SUVmax (P<0.01), while significantly positively correlated with MTV and TLG (P<0.01). The AUC (0.974) and sensitivity (92.16%) of SUVmax+MTV+TLG+serum FOXM1 in the diagnosis of lymph node metastasis were higher than those of ¹⁸F-FDG PET/CT metabolic parameters and serum FOXM1 alone, and the specificity (94.23%) was only lower than that of TLG alone. The three metabolic parameters (SUVmax, MTV and TLG) of ¹⁸F-FDG PET/CT combined with serum FOXM1 have high value in the diagnosis of lymph node metastasis.

Key words: colorectal cancer, ¹⁸F-FDG PET/CT, metabolic parameters, forkhead box protein M1, lymph node metastasis

WANF Ping, XIE Lixuan. Application of ¹⁸F-FDG PET/CT Metabolic Parameters Combined with Serum FOXM1 in the Diagnosis of Lymph Node Metastasis in Colorectal Cancer[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1570-1575.

References

[1] Gu M J, Huang Q C, Bao C Z, et al. Attributable causes of colorectal cancer in China[J]. BMC Cancer, 2018, 18(1):38.
[2] Arriola E, Navarro M, Parés D, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer[J]. Diseases of the Colon and Rectum, 2006, 49(4):478-484.
[3] Guney I B, Teke Z, Kucuker K A, et al. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and ¹⁸F-FDG PET/CT in the preoperative staging of colorectal cancer patients[J]. Annali Italiani di Chirurgia, 2020, 91:658-667.
[4] Lee D H, Lee J M. Whole-body PET/MRI for colorectal cancer staging:Is it the way forward?[J]. Journal of Magnetic Resonance Imaging, 2017, 45(1):21-35.
[5] Tsili A C, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT:A meta-analysis[J]. Acta Radiologica:Stockholm, Sweden:1987, 2021, 62(3):302-312.
[6] Caresia Aroztegui A P, García Vicente A M, Alvarez Ruiz S, et al. ¹⁸F-FDG PET/CT in breast cancer:Evidence-based recommendations in initial staging[J]. Tumour Biology, 2017, 39(10):1010428317728285.
[7] Castello A, Rossi S, Lopci E. ¹⁸F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer:State of the art[J]. Current Radiopharmaceuticals, 2020, 13(3):228-237.
[8] Paydary K, Seraj S M, Zadeh M Z, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Molecular Imaging and Biology, 2019, 21(1):1-10.
[9] 黄慧. ¹⁸F-FDG PET/CT显像在结直肠癌术后复发中的应用价值[D]. 天津:天津医科大学, 2015.
[10] 田蓉蓉, 薄云峰, 张毅勋, 等. ¹⁸F-FDG PET/CT术前诊断结直肠癌区域淋巴结转移的价值[J]. 中国医学影像学杂志, 2017, 25(11):801-806.
[11] 王大龙, 于丽娟, 田墨涵, 等. ¹⁸F-FDG PET/CT显像在结直肠癌术前分期中的价值[J]. 临床放射学杂志, 2012, 31(1):70-74.
[12] Gartel A L. FOXM1 in cancer:Interactions and vulnerabilities[J]. Cancer Research, 2017, 77(12):3135-3139.
[13] Liao G B, Li X Z, Zeng S, et al. Regulation of the master regulator FOXM1 in cancer[J]. Cell Communication and Signaling, 2018, 16(1):57.
[14] Yao S, Fan L Y N, Lam E W F. The FOXO3-FOXM1 axis:A key cancer drug target and a modulator of cancer drug resistance[J]. Seminars in Cancer Biology, 2018, 50:77-89.
[15] Li Q, Zhang N, Jia Z L, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression[J]. Cancer Research, 2009, 69(8):3501-3509.
[16] Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression[J]. Scientific Reports, 2019, 9(1):1505.
[17] Yang Y H, Jiang H Q, Li W X, et al. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer[J]. Aging, 2020, 12(23):24424-24440.
[18] Biller L H, Schrag D. Diagnosis and treatment of metastatic colorectal cancer:A review[J]. JAMA, 2021, 325(7):669-685.
[19] Dekker E, Tanis P J, Vleugels J L A, et al. Colorectal cancer[J]. Lancet:London, England, 2019, 394(10207):1467-1480.
[20] Sokolovi E, Ceri T, Ceri Š, et al. The Prognostic value of SUVmax of ¹⁸F-FDG PET/CT in patients with metastatic colorectal cancer[J]. Acta Medica Academica, 2020, 49(1):1-8.
[21] Kaida H, Toh U, Hayakawa M, et al. The relationship between ¹⁸F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer[J]. Nuclear Medicine Communications, 2013, 34(6):562-570.
[22] Kim D H, Song B I, Hong C M, et al. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41(11):2051-2057.
[23] Im H J, Oo S, Jung W, et al. Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer[J]. Medicine, 2016, 95(19):e3686.
[24] Ogawa S, Itabashi M, Kondo C, et al. Prognostic value of total lesion glycolysis measured by ¹⁸F-FDG-PET/CT in patients with colorectal cancer[J]. Anticancer Research, 2015, 35(6):3495-3500.
[25] 丁重阳, 郭喆, 孙晋, 等. 18氟-氟代脱氧葡萄糖PET/CT检查判断胰腺癌预后的临床价值[J]. 中华消化外科杂志, 2017, 16(10):1072-1080.
[26] Xu J Y, Li Y, Hu S L, et al. The significant value of predicting prognosis in patients with colorectal cancer using (18)F-FDG PET metabolic parameters of primary tumors and hematological parameters[J]. Annals of Nuclear Medicine, 2019, 33(1):32-38.
[27] Chen S W, Chen W T L, Wu Y C, et al. Which FDG/PET parameters of the primary tumors in colon or sigmoid cancer provide the best correlation with the pathological findings?[J]. European Journal of Radiology, 2013, 82(9):e405-e410.
[28] 贾朝阳. ¹⁸F-FDG PET/CT显像在结直肠癌中的应用价值[D]. 天津:天津医科大学, 2019.
[29] Lin J Z, Wang W W, Hu T T, et al. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy[J]. Cancer Letters, 2020, 469:481-489.
[30] Ros S, Wright A J, D’Santos P, et al. Metabolic imaging detects resistance to PI3Kα inhibition mediated by persistent FOXM1 expression in ER(+) breast cancer[J]. Cancer Cell, 2020, 38(4):516-533.e9.
[31] Sun H L, Men J R, Liu H Y, et al. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner[J]. Archives of Biochemistry and Biophysics, 2020, 685:108349.
[32] Zhang S C, Zhao B S, Zhou A D, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J]. Cancer Cell, 2017, 31(4):591-606.e6.
[33] 袁浩, 李永平, 蒋晓飞, 等. 抑制FoxM1基因表达对甲状腺乳头状癌TPC-1细胞糖酵解途径的影响[J]. 肿瘤防治研究, 2019, 46(4):289-293.

Application of ¹⁸F-FDG PET/CT Metabolic Parameters Combined with Serum FOXM1 in the Diagnosis of Lymph Node Metastasis in Colorectal Cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 14

Recommended Articles

Metrics

Comments

[1]	LI Haoran, ZHANG Peng, CHEN Chong. Diagnostic Value of Spectral CT in Lymph Node Metastasis in Gastric Cancer and Analysis of Influencing Factors [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1390-1395.
[2]	LAN Hao, ZHAN Rui, WANG Yue, ZHANG Xiaoqin. Comparison of Ultrasound-guided ESP and TAP in the Treatment Effect of Colorectal Cancer Patients Undergoing Radical Resection [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1455-1459.
[3]	GAO Jie, PENG Yuexiang, ZHAO Shanshan, LUO Chi, GAO Weiyuan. The Value of Ultrasound Elastography Combined with Mts1 Protein in the Diagnosis of Thyroid Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1460-1464.
[4]	ZHANG Jian, REN Xiaoyan. Application of Spectral CT Combined with Long Non-coding RNA UCA1 in the Diagnosis of Lymph Node Metastasis of Gastric Adenocarcinoma [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(6): 1539-1544.
[5]	YAO Yujie, DU Chunling, LIU Yaning, ZHANG Chai. Diagnostic Analysis for Multi-slice Spiral CT Combined with miR-142-5p in Diagnosis of Cervical Cancer Lymph Node Metastasis [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(4): 902-906.
[6]	GAN Meixiang, LI Qiulan, ZHANG Xiaodan. Application of MRI in Diagnosis of Cervical Lymph Node Metastasis Caused by Tongue Squamous Cell Carcinoma [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(4): 947-951.
[7]	ZHANG Xiaojie, LI Na, YANG Fang, HOU Qianqian, LI Lingling, CAI Hongxu. The Value of ¹⁸F-FDG PET/CT Technology in Evaluating the Effect of T2DM on the Efficacy of PD-L1 Targeted Therapy in Patients with Advanced Colorectal Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(2): 237-242.
[8]	LI Zhaoxi, WEN Dehui, LU Haiyong, LIU Weiliang. Application Effects of Different Ultrasound Techniques and TI-RADS in Lymph Node Metastasis of Thyroid Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(2): 335-338.
[9]	CAI Li, QUAN Xiang. The Value of Enhanced CT Combined with Serum Markers in the Diagnosis of Colorectal Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(1): 43-47.
[10]	LI Xiaoling, SU Jiemin, WANG Zhenping. The Value of MR-DWI Imaging in Predicting Axillary Lymphatic Metastasis of Breast Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(1): 170-174.
[11]	DONG Jun, LIU Jun. Diagnostic Value of Ultrasound Features in Lymph Node Metastasis of PTMC [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(6): 875-878.
[12]	ZAHNG Shuo, WANG Shuwen, GUO Xuemin, XU Hong, WANG Yanxiang, ZHANG Xia, YANG Li. Value of Three-dimensional Tomographic Ultrasound Combined with Contrast-enhanced Ultrasound in the Evaluation in Patients with DTC [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(6): 896-901.
[13]	ZOU Huayu, ZHOU Yinpin. Diagnostic Value of CT Combined with High Resolution Pelvic MRI in Colorectal Cancer [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(3): 479-482.
[14]	LIU Songyu, WU Fangfang, XU Shanshan. The Correlation Between Ultrasound Features and Cervical Lymph Node Metastasis of Thyroid Cancer [J]. Imaging Science and Photochemistry, 2020, 38(4): 647-651.